Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1603

1.

Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12 h regimen of N-acetylcysteine for paracetamol overdose (POP trial).

Morrison EE, Oatey K, Gallagher B, Grahamslaw J, O'Brien R, Black P, Oosthuyzen W, Lee RJ, Weir CJ, Henriksen D, Dear JW; POP Trial Investigators.

EBioMedicine. 2019 Jul 13. pii: S2352-3964(19)30448-7. doi: 10.1016/j.ebiom.2019.07.013. [Epub ahead of print]

2.

Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?

Grossman HB, Bellmunt J, Black PC.

Eur Urol Oncol. 2019 Jul 3. pii: S2588-9311(19)30077-X. doi: 10.1016/j.euo.2019.06.002. [Epub ahead of print]

3.

Treatment Outcomes and Dose Rate Effects Following Gamma Knife Stereotactic Radiosurgery for Vestibular Schwannomas.

Smith DR, Saadatmand HJ, Wu CC, Black PJ, Wuu YR, Lesser J, Horan M, Isaacson SR, Wang TJC, Sisti MB.

Neurosurgery. 2019 Jul 4. pii: nyz229. doi: 10.1093/neuros/nyz229. [Epub ahead of print]

PMID:
31270543
4.

Co-administration of a Rhododendron tomentosum extract does not affect mercury tissue concentrations and excretion rate in methylmercury-treated adult male rats.

Pelletier G, Feng YL, Leingartner K, Black P.

BMC Res Notes. 2019 Jul 1;12(1):369. doi: 10.1186/s13104-019-4409-7.

5.

Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?

Rouprêt M, Malmstrom PU, Black P.

Eur Urol Oncol. 2019 Jun 22. pii: S2588-9311(19)30078-1. doi: 10.1016/j.euo.2019.06.003. [Epub ahead of print]

6.

Author Correction: Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.

Korpal M, Puyang X, Wu ZJ, Seiler R, Furman C, Oo HZ, Seiler M, Irwin S, Subramanian V, Joshi JJ, Wang CK, Rimkunas V, Tortora D, Yang H, Kumar N, Kuznetsov G, Matijevic M, Chow J, Kumar P, Zou J, Feala J, Corson L, Henry R, Selvaraj A, Davis A, Bloudoff K, Douglas J, Kiss B, Roberts M, Fazli L, Black PC, Fekkes P, Smith PG, Warmuth M, Yu L, Hao MH, Larsen N, Daugaard M, Zhu P.

Nat Commun. 2019 Jun 4;10(1):2527. doi: 10.1038/s41467-019-10666-3.

7.

Changes in lipid classes of Drosophila melanogaster in response to selection for three stress traits.

Ko L, Harshman L, Hangartner S, Hoffmann A, Kachman S, Black P.

J Insect Physiol. 2019 May 30;117:103890. doi: 10.1016/j.jinsphys.2019.103890. [Epub ahead of print]

PMID:
31153895
8.

Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.

Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC.

Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15. Review.

PMID:
31102625
9.

Development and acceptability testing of a patient decision aid for urinary diversion with radical cystectomy.

McAlpine K, Lavallée LT, Stacey D, Moodley P, Cagiannos I, Morash C, Black PC, Kulkarni GS, Shayegan B, Kassouf W, Siemens R, So A, Leveridge MJ, Boorjian SA, Daneshmand S, Smith AB, Power N, Izawa J, Drachenberg DE, Fairey A, Rendon RA, Breau RH.

J Urol. 2019 May 17:101097JU0000000000000341. doi: 10.1097/JU.0000000000000341. [Epub ahead of print]

PMID:
31099720
10.

Detection of physiological deterioration by the SNAP40 wearable device compared to standard monitoring devices in the emergency department: the SNAP40-ED study.

Reed MJ, McGrath M, Black PL, Lewis S, McCann C, Whiting S, O'Brien R, Grant A, Harrison B, Skyrme L, Odam M.

Diagn Progn Res. 2018 Sep 3;2:18. doi: 10.1186/s41512-018-0040-7. eCollection 2018.

11.

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA.

Eur Urol. 2019 Aug;76(2):200-206. doi: 10.1016/j.eururo.2019.04.036. Epub 2019 May 12.

PMID:
31092337
12.

Molecular landscape of carcinoma invading bladder muscle: does patient age matter?

Seiler R, Wyatt AW, Black PC.

BJU Int. 2019 May 9. doi: 10.1111/bju.14802. [Epub ahead of print] No abstract available.

PMID:
31074172
13.

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma.

Warren M, Kolinsky M, Canil CM, Czaykowski P, Sridhar SS, Black PC, Booth CM, Kassouf W, Eapen L, Mukherjee SD, Blais N, Eigl BJ, Winquist E, Basappa NS, North SA; GUMOC.

Can Urol Assoc J. 2019 Apr 26. doi: 10.5489/cuaj.6015. [Epub ahead of print] No abstract available.

PMID:
31059420
14.

Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer.

Meng MV, Gschwend JE, Shore N, Grossfeld GD, Mostafid H, Black PC.

J Urol. 2019 May 1:101097JU0000000000000297. doi: 10.1097/JU.0000000000000297. [Epub ahead of print]

PMID:
31042108
15.

Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer.

Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL.

Eur Urol Oncol. 2019 Mar;2(2):119-125. doi: 10.1016/j.euo.2018.07.006. Epub 2018 Aug 14.

PMID:
31017086
16.

Fatty acid transport protein 2 reprograms neutrophils in cancer.

Veglia F, Tyurin VA, Blasi M, De Leo A, Kossenkov AV, Donthireddy L, To TKJ, Schug Z, Basu S, Wang F, Ricciotti E, DiRusso C, Murphy ME, Vonderheide RH, Lieberman PM, Mulligan C, Nam B, Hockstein N, Masters G, Guarino M, Lin C, Nefedova Y, Black P, Kagan VE, Gabrilovich DI.

Nature. 2019 May;569(7754):73-78. doi: 10.1038/s41586-019-1118-2. Epub 2019 Apr 17.

PMID:
30996346
17.

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC.

Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5.

PMID:
30952638
18.

Clinical and Bacterial Risk Factors for Development of Post-Prostate Biopsy Infections.

Hasanzadeh A, Black P, Pourmand MR, Pourmand G.

Urol J. 2019 Mar 18. doi: 10.22037/uj.v0i0.4603. [Epub ahead of print]

19.

New horizons in bladder cancer research.

Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ.

Urol Oncol. 2019 Mar 7. pii: S1078-1439(18)30508-8. doi: 10.1016/j.urolonc.2018.12.014. [Epub ahead of print] Review.

PMID:
30852032
20.

Comparison of Artificial Intelligence Techniques to Evaluate Performance of a Classifier for Automatic Grading of Prostate Cancer From Digitized Histopathologic Images.

Nir G, Karimi D, Goldenberg SL, Fazli L, Skinnider BF, Tavassoli P, Turbin D, Villamil CF, Wang G, Thompson DJS, Black PC, Salcudean SE.

JAMA Netw Open. 2019 Mar 1;2(3):e190442. doi: 10.1001/jamanetworkopen.2019.0442.

21.

Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Kulkarni GS, Black PC, Sridhar SS, Kapoor A, Zlotta AR, Shayegan B, Rendon R, Chung P, Van Der Kwast T, Alimohamed N, Fradet Y, Kassouf W.

Can Urol Assoc J. 2019 Jan 31. doi: 10.5489/cuaj.5902. [Epub ahead of print] No abstract available.

PMID:
30763236
22.

Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.

Lavoie JM, Black PC, Eigl BJ.

J Urol. 2019 Jul;202(1):49-56. doi: 10.1097/JU.0000000000000136. Epub 2019 Jun 7.

23.

Wearable technology-based metrics for predicting operator performance during cardiac catheterisation.

Currie J, Bond RR, McCullagh P, Black P, Finlay DD, Gallagher S, Kearney P, Peace A, Stoyanov D, Bicknell CD, Leslie S, Gallagher AG.

Int J Comput Assist Radiol Surg. 2019 Apr;14(4):645-657. doi: 10.1007/s11548-019-01918-0. Epub 2019 Feb 7.

24.

Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT.

Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1.

PMID:
30712971
25.

Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series1.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ.

Urol Oncol. 2019 Jan 22. pii: S1078-1439(19)30003-1. doi: 10.1016/j.urolonc.2019.01.003. [Epub ahead of print] Review.

PMID:
30683454
26.

Global, Regional and National Burden of Bladder Cancer, 1990 to 2016: Results from the GBD Study 2016.

Ebrahimi H, Amini E, Pishgar F, Moghaddam SS, Nabavizadeh B, Rostamabadi Y, Aminorroaya A, Fitzmaurice C, Farzadfar F, Nowroozi MR, Black PC, Daneshmand S.

J Urol. 2019 May;201(5):893-901. doi: 10.1097/JU.0000000000000025.

PMID:
30676477
27.

SIU-ICUD consultation on bladder cancer 2018.

Black P, Gontero P.

World J Urol. 2019 Jan;37(1):1-2. doi: 10.1007/s00345-018-2601-3. No abstract available.

PMID:
30666399
28.

Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.

Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, Herberts C, Ritch E, Beja K, Loktionova Y, Hurtado-Coll A, Fazli L, So A, Black PC, Nykter M, Tammela T, Chi KN, Gleave ME, Wyatt AW.

Eur Urol. 2019 Apr;75(4):667-675. doi: 10.1016/j.eururo.2018.12.042. Epub 2019 Jan 10.

PMID:
30638634
29.

Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study.

Sabouri S, Chang SD, Goldenberg SL, Savdie R, Jones EC, Black PC, Fazli L, Kozlowski P.

NMR Biomed. 2019 Feb;32(2):e4048. doi: 10.1002/nbm.4048. Epub 2018 Dec 21.

PMID:
30575145
30.

Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes.

Voskuilen CS, Seiler R, Rink M, Poyet C, Noon AP, Roghmann F, Necchi A, Aziz A, Lavollé A, Young MJ, Marks P, Saba K, van Rhijn BWG, Fransen van de Putte EE, Ablat J, Black PC, Sosnowski R, Dobruch J, Kumar P, Jallad S, Catto JWF, Xylinas E, Hendricksen K; Young Academic Urologists’ Working Group on Urothelial Carcinoma of the European Association of Urology.

Eur Urol Focus. 2018 Dec 14. pii: S2405-4569(18)30382-1. doi: 10.1016/j.euf.2018.12.002. [Epub ahead of print]

PMID:
30559065
31.

Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.

da Costa JB, Gibb EA, Nykopp TK, Mannas M, Wyatt AW, Black PC.

Urol Oncol. 2018 Dec 8. pii: S1078-1439(18)30463-0. doi: 10.1016/j.urolonc.2018.11.015. [Epub ahead of print] Review.

PMID:
30528886
32.

Conservative management of hostile bladders with intravesical botulinum toxin for successful renal transplantation.

Niu S, Black P, Padmanabhan P.

Urol Case Rep. 2018 Oct 25;22:73-75. doi: 10.1016/j.eucr.2018.10.017. eCollection 2019 Jan. No abstract available.

33.

Immune regulation and anti-cancer activity by lipid inflammatory mediators.

Khadge S, Sharp JG, McGuire TR, Thiele GM, Black P, DiRusso C, Cook L, Klassen LW, Talmadge JE.

Int Immunopharmacol. 2018 Dec;65:580-592. doi: 10.1016/j.intimp.2018.10.026. Epub 2018 Nov 14. Review.

PMID:
30447537
34.

Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer.

Ingersoll MA, Li X, Inman BA, Greiner JW, Black PC, Adam RM.

Bladder Cancer. 2018 Oct 29;4(4):429-440. doi: 10.3233/BLC-180175.

35.

Experimental studies on zeta potential of flocculants for harvesting of algae.

Pandey A, Pathak VV, Kothari R, Black PN, Tyagi VV.

J Environ Manage. 2019 Feb 1;231:562-569. doi: 10.1016/j.jenvman.2018.09.096. Epub 2018 Oct 30.

PMID:
30388653
36.

Current Clinical Trials in Non-muscle Invasive Bladder Cancer.

Nykopp TK, Batista da Costa J, Mannas M, Black PC.

Curr Urol Rep. 2018 Oct 24;19(12):101. doi: 10.1007/s11934-018-0852-6. Review.

PMID:
30357541
37.

An investigation of clinical treatment field delivery verification using cherenkov imaging: IMRT positioning shifts and field matching.

Black PJ, Velten C, Wang YF, Na YH, Wuu CS.

Med Phys. 2019 Jan;46(1):302-317. doi: 10.1002/mp.13250. Epub 2018 Nov 19.

PMID:
30346639
38.

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN.

Eur Urol Oncol. 2018 Jun;1(2):91-100. doi: 10.1016/j.euo.2018.03.005. Epub 2018 Jun 6.

39.

Post-translational modifications in bladder cancer: Expanding the tumor target repertoire.

Oo HZ, Seiler R, Black PC, Daugaard M.

Urol Oncol. 2018 Oct 17. pii: S1078-1439(18)30339-9. doi: 10.1016/j.urolonc.2018.09.001. [Epub ahead of print] Review.

PMID:
30342880
40.

Automatic grading of prostate cancer in digitized histopathology images: Learning from multiple experts.

Nir G, Hor S, Karimi D, Fazli L, Skinnider BF, Tavassoli P, Turbin D, Villamil CF, Wang G, Wilson RS, Iczkowski KA, Lucia MS, Black PC, Abolmaesumi P, Goldenberg SL, Salcudean SE.

Med Image Anal. 2018 Dec;50:167-180. doi: 10.1016/j.media.2018.09.005. Epub 2018 Sep 24.

PMID:
30340027
41.

Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival.

Khadge S, Thiele GM, Sharp JG, McGuire TR, Klassen LW, Black PN, DiRusso CC, Cook L, Talmadge JE.

Clin Exp Metastasis. 2018 Dec;35(8):797-818. doi: 10.1007/s10585-018-9941-7. Epub 2018 Oct 16.

PMID:
30327985
42.

A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy.

Hwang ME, Black PJ, Elliston CD, Wolthuis BA, Smith DR, Wu CC, Wenske S, Deutsch I.

Radiat Oncol. 2018 Oct 1;13(1):192. doi: 10.1186/s13014-018-1135-6.

43.

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.

Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF.

Eur Urol. 2018 Dec;74(6):784-795. doi: 10.1016/j.eururo.2018.09.001. Epub 2018 Sep 26.

PMID:
30268659
44.

Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.

Todenhöfer T, Seiler R, Stewart C, Moskalev I, Gao J, Ladhar S, Kamjabi A, Al Nakouzi N, Hayashi T, Choi S, Wang Y, Frees S, Daugaard M, Oo HZ, Fisel P, Schwab M, Schaeffeler E, Douglas J, Hennenlotter J, Bedke J, Gibb EA, Fazli L, Stenzl A, Black PC.

Mol Cancer Ther. 2018 Dec;17(12):2746-2755. doi: 10.1158/1535-7163.MCT-18-0107. Epub 2018 Sep 27.

PMID:
30262589
45.

Critical Questions To Optimize Intravesical Therapy for Non-muscle-invasive Bladder Cancer.

Black P.

Eur Urol Focus. 2018 Jul;4(4):463. doi: 10.1016/j.euf.2018.09.004. Epub 2018 Sep 24. No abstract available.

PMID:
30262197
46.

Induction of oil accumulation by heat stress is metabolically distinct from N stress in the green microalgae Coccomyxa subellipsoidea C169.

Allen JW, Tevatia R, Demirel Y, DiRusso CC, Black PN.

PLoS One. 2018 Sep 27;13(9):e0204505. doi: 10.1371/journal.pone.0204505. eCollection 2018.

47.

Immune system trickery and deception: Allograft-derived neuroendocrine carcinoma post kidney transplantation.

Chehroudi C, Mannas M, Jones EC, Nguan C, Oja C, Black PC.

Urol Case Rep. 2018 Sep 14;21:89-91. doi: 10.1016/j.eucr.2018.09.007. eCollection 2018 Nov. No abstract available.

48.

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2018 Sep 17. doi: 10.1158/1078-0432.CCR-18-1106. [Epub ahead of print]

PMID:
30224344
49.

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.

Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB.

Eur Urol Focus. 2018 Jul;4(4):512-521. doi: 10.1016/j.euf.2018.08.019. Epub 2018 Sep 3.

PMID:
30190111
50.

Enhancing the quality of life for stoma patients with appropriate accessory use.

Black P.

Br J Nurs. 2018 Sep 6;27(16):S14. doi: 10.12968/bjon.2018.27.16.S14. No abstract available.

PMID:
30187796

Supplemental Content

Support Center